Phathom Pharmaceuticals, Inc. (PHAT)
Nasdaq · Healthcare · Biotechnology
$6.70−3.18%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $542M
- Forward P/E
- 6.2
- 52-week range
- $6.65 – $18.31
- 52-week change
- −36.16%
- EPS (trailing)
- −$1.26
- Next earnings
- Oct 29, 2026
Fiscal year to Dec 2025
- Revenue
- $175M (+216.93%)
- Net income
- −$221K
- Operating margin
- −91.4%
- Diluted EPS
- −$3.03
- Free cash flow
- −$167M
From the company’s annual report on SEC EDGAR.
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Headquarters: Florham Park, United States · 371 employees · phathompharma.com